Apogee Therapeutics shares face Nasdaq suspension as company moves to delist after AbbVie merger - APGE News | RalliesApogee Therapeutics shares face Nasdaq suspension as company moves to delist after AbbVie merger
A
APGE• Nasdaq suspension and delisting plans
- Apogee notified Nasdaq of its merger close, requesting delisting and continued trading halt; shares suspended from trading Sept. 4, 2026.
- Nasdaq to file SEC Form 25 to delist and deregister the stock under Exchange Act Section 12(b).
- Company plans to file SEC Form 15 to terminate registration under Section 12(g), suspending reporting obligations under Sections 13 and 15(d).
•
